EUVIMEDEUVIMED entdecken
Open Access

Real-world assessment of effectiveness and safety of filgotinib in 286 patients with ulcerative colitis in 9 UK centres

David Young iD, Sohail Rahmany, Deborah Taylor, Emma Davis, Michael Colwill, Sonia Kalyanji Mehta, Roisin Campbell, Karl Hazel, Karishma Sethi-Arora, Susan Ritchie, Ashley I Heinson, Helen Moyses und 10 weitere

Drugs in Context · 29.01.2025 · 14 · 1-14

DOI: 10.7573/dic.2024-11-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drugs in Context, online erschienen am 29.01.2025. Verfasst von David Young und 21 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital Southampton NHS Foundation Trust, Southampton, UK. Die Arbeit wurde bisher 12-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Filgotinib, an oral Janus kinase 1 preferential inhibitor, has been shown to be an effective treatment for ulcerative colitis (UC) in pre-registration studies. We aimed to describe the treatment population, effectiveness and safety of filgotinib in a real-world cohort of patients with UC.

Methods

A retrospective observational cohort evaluation was conducted across nine UK inflammatory bowel disease centres. Baseline demographic and clinical data, clinical disease activity scores, endoscopic activity indices, and biomarkers (C-reactive protein and faecal calprotectin) were collected at baseline, at 8-12 weeks after initiation (post-induction) and during maintenance (the most recent review) where available. Effectiveness outcomes were assessed in patients with combined clinical disease activity and objective evidence of inflammation at filgotinib initiation.

Results

Data were analysed for a total of 286 patients with a median follow-up time of 229 (IQR 113-324) days. The median age at filgotinib initiation was 38 (IQR 27-51) years, 64% were men and median disease duration was 5.1 (IQR 1.9-10.5) years; 56% had previous exposure to advanced therapies (biologics and small molecule) and 6% previously received tofacitinib. At the post-induction review, clinical response and remission were achieved in 65% and 51% of patients, respectively. There was a reduction in biomarkers and 78% of patients using corticosteroids at baseline were steroid-free. Persistence on filgotinib at 12 months was 66%. Adverse events were recorded in 30 patients with 8 patients discontinuing filgotinib as a result of an adverse event.

Conclusions

In a large real-world cohort of patients with UC, filgotinib appears to be effective and well-tolerated.

Schlagwörter

Stichwörter der Autor:innen

colitisfilgotinibquality of lifeulcerative colitis

Autor:innen und Institutionen

  • University Hospital Southampton NHS Foundation Trust, Southampton, UK.
  • University of Southampton, Southampton, UK.
  • Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • St George's University Hospitals NHS Foundation Trust, London, UK.
  • NHS Greater Glasgow & Clyde, Glasgow, UK.
  • University Hospitals Birmingham NHS Trust, Birmingham, UK.

ORCID-Profile: David Young

Zitieren

APA

Young, D., Rahmany, S., Taylor, D., Davis, E., Colwill, M., Kalyanji Mehta, S., Campbell, R., Hazel, K., Sethi-Arora, K., Ritchie, S., Heinson, A. I., Moyses, H., Bodger, K., Johnston, E., Hicks, L., Dhar, A., Limdi, J., Cooney, R., Seenan, J. P., …, & Cummings, F. (2025). Real-world assessment of effectiveness and safety of filgotinib in 286 patients with ulcerative colitis in 9 UK centres. Drugs in Context, 14, 1-14. https://doi.org/10.7573/dic.2024-11-1

Vancouver

Young D, Rahmany S, Taylor D, Davis E, Colwill M, Kalyanji Mehta S, et al. Real-world assessment of effectiveness and safety of filgotinib in 286 patients with ulcerative colitis in 9 UK centres. Drugs in Context. 2025;14:1-14. doi:10.7573/dic.2024-11-1

BibTeX
@article{Young2025,
  author = {Young, David and Rahmany, Sohail and Taylor, Deborah and Davis, Emma and Colwill, Michael and Kalyanji Mehta, Sonia and Campbell, Roisin and Hazel, Karl and Sethi-Arora, Karishma and Ritchie, Susan and Heinson, Ashley I and Moyses, Helen and Bodger, Keith and Johnston, Emma and Hicks, Lucy and Dhar, Anjan and Limdi, Jimmy and Cooney, Rachel and Seenan, John Paul and Patel, Kamal and Walsh, Alissa and Cummings, Fraser},
  title = {Real-world assessment of effectiveness and safety of filgotinib in 286 patients with ulcerative colitis in 9 UK centres},
  journal = {Drugs in Context},
  year = {2025},
  volume = {14},
  pages = {1--14},
  doi = {10.7573/dic.2024-11-1}
}
Kostenlos starten →